Skip to main content

News and blog posts

01
Feb 2024

2024/25 National Genomic Test Directory released in England

In January 2024, NHS England issued an updated version of the National Genomic Test Directory for 2024/2025, which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Six new codes (test-indication combinations) were introduced in the Test Directory for cancer, and four new codes in the Test Directory for rare and inherited diseases.
31
Jan 2024

2024 APR-DRG system released in Belgium

On January 15, 2024, the National Institute for Health and Disability Insurance (INAMI-RIZIV) released an updated DRG system for 2024. No significant changes were made aand no new APR-DRGs were added; thus. The reimbursement tariffs were increased by about 5%.
30
Jan 2024

Approval of uniform financing of outpatient and inpatient care in Switzerland

In December 2023, the Swiss parliament adopted the uniform financing of outpatient and inpatient services (EFAS). Currently, inpatient benefits are financed jointly by health insurers and the cantons, whereas outpatient services are entirely funded by the insured. The EFAS will come into force in January 2028 and bring a uniform way of financing inpatient and outpatient services; the healthcare system is expected to be integrated into this system four years later.
30
Jan 2024

Publication Digest: Integration of real-world evidence from different data sources in health technology assessment

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Graili et al. reviewed the comprehensive integration of real-world evidence (RWE) drawn from diverse sources of real-world data (RWD) within the health technology assessment (HTA) process. The authors examined the potential challenges and barriers that impede the widespread incorporation of RWE in routine HTA practices. The study sheds light on the effective utilization of RWE, offering insights into the strategic application of RWD at different stages of the HTA process, thus advocating for a more robust and inclusive approach to evidence-based decision-making in healthcare.
29
Jan 2024

MTRC expanded short overviews of reimbursement systems in the Knowledge Zone domain to 31 EU countries

MTRC maintains a page with free, brief summaries of the market access landscape for medical technologies and in-vitro diagnostic tests in European countries, the Knowledge Zone. The intention of the Knowledge Zone is to become an easily accessible reference material to our clients about payment systems for medical technologies in Europe. The current version of the Knowledge Zone includes information about 30 countries: Austria, Belgium, Bulgaria, Croatia, the Czech Republic, Denmark, England, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxemburg, the Netherlands, Norway, Poland, Portugal, Romania, Scotland, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and Wales. For each country, information is provided about key market access challenges, payment mechanisms, funding and HTA barriers, and specifics of reimbursement of in-vitro diagnostic (IVD) tests.
26
Jan 2024

2024 Finnish NordDRG system came into force

On January 1, 2024, the annual update of the Finnish NordDRG system came into force. A total of 63 new DRGs were introduced concerning men’s health, nephrology and urology, neurology, neuromodulation, obstetrics and gynecology, surgical procedures, and other fields.
25
Jan 2024

MTRC released a White Paper assessing evidence requirements of the NICE's early value assessment (EVA) program in the UK

Health technology assessment plays an important role in market access for medical technologies in England. NICE's early value assessment (EVA) program in medical technology, launched in 2022, assesses mostly digital technologies at an early stage in evidence generation. The program recommends the most promising technologies for use in the NHS while further evidence is being generated. NICE focuses on clinical effectiveness, safety, cost, and cost-effectiveness of the technologies. In this White Paper, MTRC performed a review of five recent EVA assessments by NICE to present the evidence requirements for digital and diagnostic medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE.
25
Jan 2024

MTRC released a White Paper on the topic of the evidence gap analysis for medical technologies

Medical technologies face several market access challenges in Europe, including reimbursement, funding (post-reimbursement approval by payers), and health technology assessment. To overcome some of these challenges, Med Tech companies need to develop clinical and economic evidence to support the value claims about medical technologies. MTRC helps medical technology companies reduce uncertainty about evidence requirements of key European reimbursement, funding, and HTA authorities and develop a clear plan to address key gaps with clinical and economic evidence. A White Paper "Evidence Gap Analysis for Medical Technologies in Europe – a Practical Example" presents the methodological approach or MTRC and a practical example of evidence gap analysis.
24
Jan 2024

Four more health apps obtained reimbursement in Germany

Between early September 2023 and mid-January 2024, four more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 53 health apps are currently available in the DiGA Directory, and six health apps were delisted from the Directory.